Axonis Therapeutics
Last verified 2026-05-18. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $150.0Mattributed |
|---|---|
| Latest round | series-a, $115.0M, 2024-10-01attributed |
| Founded | 2020 |
| Headquarters | Boston, MA |
| Industry | biotechnology |
| Stage | series-a |
| Website | axonistx.com |
Axonis Therapeutics develops drugs targeting KCC2, a brain protein central to neural inhibition, with lead candidate AXN-027 for epilepsy and chronic pain. It aims to treat patients with epilepsy, pain, and other central nervous system disorders. Its proprietary KCC2 discovery engine is built on research spun out of Boston Children's Hospital, Harvard, and Laval University.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-10-01 | series-a | $115.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $115.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $150.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | axonistx.com, read 2026-05-18 |
| Description | self-reported | axonistx.com, read 2026-05-18 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.